Belantamab for MM: Benefit Outweighs Ocular Risk, FDA Panel Says Belantamab for MM: Benefit Outweighs Ocular Risk, FDA Panel Says

FDA advisers welcomed the prospect of a new drug for relapsed and refractory multiple myeloma (MM) but stressed the need for an REMS program to manage belantamab ' s risk to eyes.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news